Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 602 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06028828RecruitingPhase 2
Adapted conditioning for stem cell transplant
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
Orange, CaliforniaAges 18–70 - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Birmingham, AlabamaAges 18 years+ - NCT06037018RecruitingPhase 1
Study of CC312 for B-cell blood cancers
This trial tests a new drug called CC312 for people with B-cell blood cancers that have come back or stopped responding to treatment. CC312 is designed to target CD19 on cancer cells, and the study checks if it is safe and how the body handles it.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06041620Recruiting
Gene-edited stem cell therapy for beta-thalassemia
This trial tests a new treatment that uses your own blood stem cells, edited with CRISPR technology, to reduce or eliminate the need for blood transfusions in people with beta-thalassemia.
Tianjin, Tianjin MunicipalityAges 3–35 - NCT06043011Recruiting
Registry for non-Hodgkin lymphoma patients on systemic therapy
This registry tracks people with non-Hodgkin lymphoma who are starting a new line of systemic therapy. It collects information to better understand how treatments work in real life, and optionally asks you to fill out surveys about your symptoms and quality of life.
Freiburg im BreisgauAges 18 years+ - NCT06049667RecruitingPhase 1
Study of NTQ2494 tablets for advanced blood cancer
This trial tests an oral medication (NTQ2494) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the drug is safe and effective.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06066203RecruitingPhase 1/Phase 2
Study of GNC-035 for lymphoma that returned or didn't respond to treatment
This trial tests a new drug, GNC-035, for people with non-Hodgkin's lymphoma that has come back (relapsed) or stopped responding to standard treatments (refractory). The goal is to see if GNC-035 can help when other options haven't worked.
Beijing, Beijing MunicipalityAges 18–75 - NCT06071897RecruitingPhase 3
Chemo-immunotherapy for high-risk neuroblastoma
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
MoscowAges 1.5 years–18 years - NCT06082947Recruiting
Stem cell transplant with special cell depletion for children and young adults
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
Columbus, OhioAges Up to 30 years - NCT06094881RecruitingPhase 2
Obinutuzumab for teens with immune thrombocytopenia
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
TianjinAges 12–18 - NCT06102694Recruiting
Blood test to find early signs of a transplant complication
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
TianjinAges 14–70 - NCT06106360Recruiting
Using an Apple Watch and iPhone to monitor chemo patients at home
This study tests whether using an Apple Watch and a health app on your iPhone can help monitor how you're doing during chemotherapy. Doctors want to see if tracking your health at home can catch problems early and keep you safer.
Fairfax, VirginiaAges 18 years+ - NCT06107582Recruiting
Long-term study of children with immune thrombocytopenia
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
TianjinAges 6–17 - NCT06116032Recruiting
Immune profiling for cancer immunotherapy response
This trial studies immune system changes in cancer patients receiving immunotherapy, such as checkpoint inhibitors or cell therapies. It aims to understand why some people respond better than others.
Lebanon, New HampshireAges 18 years+ - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06125483Recruiting
Cord blood transplant for cancer relapse after stem cell transplant
This trial tests a second transplant using cord blood after a first stem cell transplant failed to keep the cancer away. It's for people with blood cancers like leukemia that have come back.
Suzhou, JiangsuAges 10–65 - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Aurora, ColoradoAges birth–38 years - NCT06133426Recruiting
Connected scales for blood cancer patients at home
This trial tests if using a connected scale to monitor your weight at home can help your doctors manage your treatment for aggressive non-Hodgkin's lymphoma or multiple myeloma. It may also apply if you need a stem cell transplant (autograft) for these conditions.
ParisAges 18 years+ - NCT06158269RecruitingPhase 2
DVRd treatment for newly diagnosed double-hit myeloma
This trial tests a combination of four drugs (daratumumab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with a high-risk form of multiple myeloma called double-hit myeloma. It aims to see if this drug combo can improve outcomes for those with two or more high-risk genetic changes.
TianjinAges 18–70 - NCT06168851RecruitingPhase 2
Anti-CD38 antibody for children with chronic ITP
This trial tests a new drug called anti-CD38 antibody for children and teens with chronic immune thrombocytopenia (ITP) whose platelet counts remain low despite other treatments. It may help increase platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 6–17 - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT06198842RecruitingPhase 2
Low-dose treosulfan with PTCy for Nijmegen Breakage Syndrome transplant
This trial tests a low-dose chemotherapy regimen (treosulfan) combined with a drug called PTCy to prepare children with Nijmegen Breakage Syndrome for a stem cell transplant. The goal is to reduce side effects while helping the donor cells take hold safely.
MoscowAges 3 months–21 years - NCT06219239Recruiting
Gene therapy for transfusion-dependent beta-thalassemia
This trial tests a new gene therapy for people with beta-thalassemia who need regular blood transfusions. It uses a virus to deliver a working gene into your own stem cells, then those cells are put back into your body to help your body make healthy red blood cells.
Tianjin, Tianjin MunicipalityAges 3–35 - NCT06222164Recruiting
Using leftover patient samples for research
This study uses leftover blood, bone marrow, or tissue samples that were already sent to a specific lab (LabPMM) for testing. Researchers want to study these samples to learn more about diseases and improve future tests for patients.
San Diego, CaliforniaAges 18 years+
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 602 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.